The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Advanced Malignant Neoplasm|Metastatic Cancer|Metastatic Solid Tumor|Lung Cancer|Ovarian Cancer|Endometrial Cancer|Prostate Cancer|Colorectal Cancer|Breast Cancer|Other Cancer|Locally Advanced|Head and Neck Cancer
Interventions: DRUG: PC14586|DRUG: pembrolizumab
Sponsor: PMV Pharmaceuticals, Inc
Collaborators: Merck Sharp & Dohme LLC